References

1. Boon T, Coulie PG et al. Human T cell responses against melanoma. Annu Rev Immunol. 2006;24:175-208.
2. Van den Eynde BJ, van der Bruggen P. T cell defined tumor antigens. Curr Opin Immunol. 1997;9:684-693.
3. Brasseur F, Marchand M et al. Human gene MAGE-1, which codes for a tumor-rejection antigen, is expressed by some breast tumors.[letter]. Int J Cancer 1992;52(5):839-841.
4. Brasseur F, Rimoldi D et al. Expression of MAGE genes in primary and metastatic cutaneous melanoma. Int J Cancer. 1995;63:375-380.
5. De Plaen E, Arden K et al. Structure, chromosomal localization, and expression of 12 genes of the MAGE family. Immunogenetics. 1994;40:360-369.
6. Weynants P, Lethe B et al. Expression of mage genes by non-small-cell lung carcinomas. Int J Cancer. 1994;56:826-829.
7. Jungbluth AA, Silva WAJ et al. Expression of cancer-testis (CT) antigens in placenta. Cancer Immun. 2007;7:15.
8. Boel P, Wildmann C et al. BAGE: a new gene encoding an antigen recognized on human melanomas by cytolytic T lymphocytes. Immunity. 1995;2:167-175.
9. Boon T, van der Bruggen P. Human tumor antigens recognized by T lymphocytes. J Exp Med. 1996;183:725-729.
10. Robbins PF, el-Gamil M et al. Cloning of a new gene encoding an antigen recognized by melanoma-specific HLA-A24-restricted tumor-infiltrating lymphocytes. J Immunol. 1995;154:5944-5950.
11. Bendle GM, Holler A et al. Broadly expressed tumour-associated proteins as targets for cytotoxic T lymphocyte-based cancer immunotherapy. Expert Opin Biol Ther. 2005;5:1183-1192.
12. Mitchell MS. Cancer vaccines, a critical review--Part I. Curr Opin Investig Drugs. 2002;3:140-149.
13. Lurquin C, Lethe B et al. Contrasting frequencies of antitumor and anti-vaccine T-cells in metastases of a melanoma patient vaccinated with a MAGE tumor antigen. J Exp Med. 2005;201:249-257.
14. Mitchell MS. Cancer vaccines, a critical review--Part II. Curr Opin Investig Drugs. 2002;3:150-158.
15. Berzofsky JA, Terabe M et al. Progress on new vaccine strategies for the immunotherapy and prevention of cancer. J Clin Invest. 2004;113:1515-1525.
16. Guevara-Patino JA, Engelhorn ME et al. Optimization of a self antigen for presentation of multiple epitopes in cancer immunity. J Clin Invest. 2006;116:1382-1390.
17. Acres B, Limacher JM, Bonnefoy J. Discovery and development of therapeutic cancer vaccines. Curr Opin Drug Discov Devel. 2007;10:185-192.
18. Garçon N, Chomez P, Van Mechelen M. GlaxoSmithKline Adjuvant Systems in vaccines: concepts, achievements and perspectives. Expert Rev Vaccines. 2007;6:723-739.
19. Schnurr M, Chen Q et al. Tumor antigen processing and presentation depend critically on dendritic cell type and the mode of antigen delivery. Blood. 2005;105:2465-2472.
20. Schultz ES, Lethe B et al. A MAGE-A3 peptide presented by HLA-DP4 is recognized on tumor cells by CD4+ cytolytic T lymphocytes. Cancer Res. 2000;60:6272-6275.
21. Silk AW, Finn OJ. Cancer vaccines: a promising cancer therapy against all odds. Future Oncol. 2007;3:299-306.
22. Van den Eynde B, Brichard VG. New tumor antigens recognized by T-cells. Curr Opin Immunol. 1995;7:674-681.
23. Pasare C, Medzhitov R. Toll-like receptors and acquired immunity. Semin Immunol. 2004;16:23-26.
24. Pulendran B, Ahmed R. Translating innate immunity into immunological memory: implications for vaccine development. Cell. 2006;124:849-863.
25. Parkin J, Cohen B. An overview of the immune system. Lancet. 2001;357:1777-1789.
26. Seya T, Akazawa T et al. Role of Toll-like receptors in adjuvant-augmented immune therapies. Evid Based Complement Alternat Med. 2006;3:31-8; discussion 133-7.
27. Kaisho T, Akira S. Toll-like receptors as adjuvant receptors. Biochim Biophys Acta. 2002;1589:1-13.
28. Storni T, Kundig TM et al. Immunity in response to particulate antigen-delivery systems. Adv Drug Deliv Rev. 2005;57:333-355.
29. Brichard VG, Lejeune D. GSK's antigen-specific cancer immunotherapy programme: pilot results leading to Phase III clinical development. Vaccine. 2007;25 Suppl 2:B61-71.
30. Coulie PG, Karanikas V et al. Cytolytic T-cell responses of cancer patients vaccinated with a MAGE antigen. Immunol Rev. 2002;188:33-42.
31. Karanikas V, Lurquin C et al. Monoclonal anti-MAGE-3 CTL responses in melanoma patients displaying tumor regression after vaccination with a recombinant canarypox virus. J Immunol. 2003;171:4898-4904.
32. Germeau C, Ma W et al. High frequency of antitumor T-cells in the blood of melanoma patients before and after vaccination with tumor antigens. J Exp Med. 2005;201:241-248.
33. Coulie PG, Connerotte T. Human tumor-specific T lymphocytes: does function matter more than number? Curr Opin Immunol. 2005;17:320-325.
34. Baxevanis CN, Voutsas IF et al. Tumor-specific CD4+ T lymphocytes from cancer patients are required for optimal induction of cytotoxic T-cells against the autologous tumor. J Immunol. 2000;164:3902-3912.
35. Brichard VG, Gerard C. Melanoma vaccines: achievements and perspectives. Forum (Genova). 2003;13:144-54; quiz 189.
36. Janssen EM, Lemmens EE et al. CD4+ T-cells are required for secondary expansion and memory in CD8+ T lymphocytes. Nature. 2003;421:852-856.
37. Coulie PG. Cancer immunotherapy with MAGE antigens. Suppl Tumori. 2002;1:S63-5.
38. Shedlock DJ, Shen H. Requirement for CD4 T cell help in generating functional CD8 T cell memory. Science. 2003;300:337-339.
39. Sun JC, Bevan MJ. Defective CD8 T cell memory following acute infection without CD4 T cell help. Science. 2003;300:339-342.
40. Van der Bruggen P, Traversari C et al. A gene encoding an antigen recognized by cytolytic T lymphocytes on a human melanoma. Science. 1991;254:1643-1647.
41. Van Pel A, van der Bruggen P et al. Genes coding for tumor antigens recognized by cytolytic T lymphocytes. Immunol Rev. 1995;145:229-250.
42. Boon T, Coulie P et al. Genes coding for tumor rejection antigens: perspectives for specific immunotherapy. Important Adv Oncol. 1994;53-69.
43. Lucas S, De Plaen E, Boon T. MAGE-B5, MAGE-B6, MAGE-C2, and MAGE-C3: four new members of the MAGE family with tumor-specific expression. Int J Cancer. 2000;87:55-60.
44. Lucas S, De Smet C et al. Identification of a new MAGE gene with tumor-specific expression by representational difference analysis. Cancer Res. 1998;58:743-752.
45. Lurquin C, De Smet C et al. Two members of the human MAGEB gene family located in Xp21.3 are expressed in tumors of various histological origins. Genomics. 1997;46:397-408.
46. Chomez P, De Backer O et al. An overview of the MAGE gene family with the identification of all human members of the family. Cancer Res. 2001;61:5544-5551.
47. Lucas S, Brasseur F, Boon T. A new MAGE gene with ubiquitous expression does not code for known MAGE antigens recognized by T-cells. Cancer Res. 1999;59:4100-4103.
48. Pold M, Zhou J et al. Identification of a new, unorthodox member of the MAGE gene family. Genomics. 1999;59:161-167.
49. Van Der Bruggen P, Zhang Y et al. Tumor-specific shared antigenic peptides recognized by human T-cells. Immunol Rev. 2002;188:51-64.
50. Vansteenkiste J, Zielinski M, Linder A. Final results of a multi-center, double-blind, randomized, placebo-controlled Phase II study to assess the efficacy of MAGE-A3 immunotherapeutic as adjuvant therapy in stage IB/II Non-Small Cell Lung Cancer (NSCLC). Journal of Clinical Oncology ASCO Annual Meeting Proceedings. 2007;Part I. Vol 25, No.18S:7554.
51. WHO. Fact sheet No 297, Feb 2006. Available at http://www.who.int/mediacentre/factsheets/fs297/en/index.html (last accessed June 8, 2008).
52. American Cancer Society. Cancer Facts and Figures 2008. Available at http://www.cancer.org/downloads/STT/2008CAFFfinalsecured.pdf (last accessed June 8, 2008). 2008
53. Sienel W, Varwerk C et al. Melanoma associated antigen (MAGE)-A3 expression in Stages I and II non-small cell lung cancer: results of a multi-center study. Eur J Cardiothorac Surg. 2004;25:131-134.
54. Gure AO, Chua R et al. Cancer-testis genes are coordinately expressed and are markers of poor outcome in non-small cell lung cancer. Clin Cancer Res. 2005;11:8055-8062.
55. Raz DJ, Zell JA et al. Natural history of stage I non-small cell lung cancer: implications for early detection. Chest. 2007;132:193-199.
56. Alberg AJ, Samet JM. Epidemiology of lung cancer. Chest. 2003;123:21S-49S.
57. University of Maryland Medical Centre. Non-small cell lung cancer. Available at http://www.umm.edu/patiented/articles/what_lung_cancer_000072_1.htm (last accessed June 8, 2008).
58. PathologyOutlines. Lung cancer histology. Available at http://www.pathologyoutlines.com/lungtumor.html#adenocarcinoma (last accessed June 8, 2008).
59. Anderson Manual of Medical Oncology. Part IV Lung cancer histology. Available at http://www.accessmedicine.com/content.aspx?aID=2788793&searchStr=lung (last accessed June 8, 2008).
60. Mountain CF, Dresler CM. Regional lymph node classification for lung cancer staging. Chest. 1997;111:1718-1723.
61. Diamandidis D, Huber M, Pisters K. Non-small cell lung cancer. In: Medical oncology: a comprehensive review. Available at http://cancernetwork.com/textbook/morev12.htm (last accessed November 2, 2007).
62. Pfister DG, Johnson DH et al. American Society of Clinical Oncology treatment of unresectable non-small-cell lung cancer guideline: update 2003. J Clin Oncol. 2004;22:330-353.
63. Schiller JH, Harrington D et al. Comparison of four chemotherapy regimens for advanced non-small-cell lung cancer. N Engl J Med. 2002;346:92-98.
64. Delbado C, Syz N, Michiels S. Adding a second or a third drug to a chemotherapy regimen in patients with advanced non-small-cell lung carcinoma (NSCLC): a meta-analysis of the literature. Proc Am Soc Clin Oncol. 2003;22:623 (abstract 2507).
65. De Greve J, Decoster L et al. [Targeted therapies in the treatment of non-small cell lung cancer]. Bull Cancer. 2008;95:358-364.
66. Kruit WH et al. Immunization with recombinant MAGE-A3 protein combined with adjuvant systems AS15 or AS02B in patients with unresectable and progressive metastatic cutaneous melanoma: A randomized open-label phase II study of the EORTC Melanoma Group (16032- 18031). Journal of Clinical Oncology ASCO Annual Meeting Proceedings. 2008; Vol 25, No.15S:9065.
67. World Health Organization. How common is skin cancer? http://www.who.int/uv/faq/skincancer/en/index1.html. (last accessed 26 March, 2009).
68. Koyanagi K, Mori T et al. Association of circulating tumor cells with serum tumor-related methylated DNA in peripheral blood of melanoma patients. Cancer Res. 2006;66:6111-6117.
69. National Cancer Institute SEER Factsheet: Melanoma of the skin. http://seer.cancer.gov/statfacts/html/melan.html (last accessed 26 March, 2009).
70. European Network of Cancer Registries. Factsheet: cutaneous malignant melanoma in Europe. 2003. http://www.encr.com.fr/melanoma-factsheets.pdf (last accessed 26 March, 2009).
71. Parkin DM et al. Global cancer statistics 2002. CA Cancer J Clin. 2005;55:74-108.
72. World Health Organization. Global Burden of Disease. 2004. http://www.who.int/healthinfo/global_burden_disease/GBD_report_2004update_part2.pdf (last accessed 26 March, 2009).
73. World Health Organization. EHNIS Factsheet No 4.2, Incidence of melanoma in people aged under 55 years. 2007. (last accessed 26 March, 2009).
74. Geller AC, Miller DR et al. Melanoma incidence and mortality among US whites, 1969-1999. JAMA 2002;288(14):1719-20.
75. Cancer Research UK. UK skin cancer incidence statistics. http://info.cancerresearchuk.org/cancerstats/types/skin/incidence/ (last accessed 26 March, 2009).
76. CancerHelp, Cancer Research UK. Melanoma statistics and outlook. http://www.cancerhelp.org.uk/help/default.asp?page=5436 (last accessed 26 March, 2009).
77. Swetter, SM. Malignant melanoma. Emedicine, 2009. http://emedicine.medscape.com/article/1100753-overview (last accessed 26 March, 2009).
78. Walker G. Cutaneous melanoma. How does ultraviolet light contribute to melanocyte transformation? Future Oncol. 2008;4:841-56
79. National Cancer Institute. What you need to know about melanoma. http://www.cancer.gov/cancertopics/wyntk/melanoma/page1 (last accessed 26 March 2009).
80. Brick, W and Burgess, R. Malignant melanoma. Emedicine, 2006 http://emedicine.medscape.com/article/280245-overview (last accessed March 2009).
81. Balch CM et al. Final version of the American Joint Committee on Cancer staging system for cutaneous melanoma. J Clin Oncol. 2001;3635-3648.
82. Scottish Intercollegiate Guidelines Network. Cutaneous melanoma: a national clinical guideline. Guideline 72, 2003.
83. Manola J et al. Prognostic factors in metastatic melanoma: a pooled analysis of Eastern Cooperative Oncology Group trials. J Clin Oncol. 2000;18:3782-93.